FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946636618> ?p ?o ?g. }

• W1946636618 endingPage "2636" @default.
• W1946636618 startingPage "2629" @default.
• W1946636618 abstract "This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy.Forty-eight patients with metastatic or locally advanced soft tissue sarcoma were, following the first cycle of a combination with doxorubicin 60 mg/m2, ifosfamide 7.5 g/m2, and dacarbazine 900 mg/m2, ifosfamide 7.5 g/m2, and dacarbazine 900 mg/m2 given on days 1 to 3, randomized to receive either lenograstim 5 micrograms/kg/d by once-daily injection from day 4 to day 13, or its vehicle. For subsequent cycles, 28 patients continued on the same chemotherapy and lenograstim was systematically given as prophylactic treatment in an open manner.Following the first cycle of MAID, the duration of neutropenia was reduced in patients who received lenograstim as compared with those who received placebo, with a median duration of neutropenia ( < 0.5 x 10(9)/L neutrophils) of 0 days (range, 0 to 3) and 5 days (range, 0 to 10), respectively (P < .001). All patients who received lenograstim had recovered at least 1 x 10(9)/L neutrophils (polymorphonuclear lymphocytes [PMN]) on day 14, compared with only one of 26 in the placebo group (P < .001). The median time to recover this neutrophil level was 12 days (range, 10 to 13) and 17 days (range, 14 to 21), respectively (P < .001). Neutropenic fever occurred in five (23%) and 15 (58%) patients respectively (P = .02). Twenty-eight patients received at least two cycles (median, four) of MAID at the same dose. Toxicity remained constant across all treatment cycles. A progressive increase in thrombocytopenia was noted, with median platelet nadirs of 102 x 10(9)/L at cycle 2 and 19.5 x 10(9)/L at cycle 6, but did not result in significant treatment modifications. Consequently, median relative dose-intensities remained greater than 0.95 for up to six consecutive MAID cycles.Lenograstim significantly improved hematologic tolerance in patients treated with the MAID chemotherapy regimen and, therefore, allowed optimal adhesion to the theoretic doses planned for up to six cycles. Whether such an optimization in relative dose-intensity will result in an improvement of treatment efficacy remains to be determined." @default.
• W1946636618 created "2016-06-24" @default.
• W1946636618 creator A5005804337 @default.
• W1946636618 creator A5015619414 @default.
• W1946636618 creator A5038734791 @default.
• W1946636618 creator A5040497223 @default.
• W1946636618 creator A5049406196 @default.
• W1946636618 creator A5056213861 @default.
• W1946636618 creator A5068977568 @default.
• W1946636618 creator A5076354847 @default.
• W1946636618 creator A5085647218 @default.
• W1946636618 creator A5085936617 @default.
• W1946636618 date "1995-10-01" @default.
• W1946636618 modified "2023-09-27" @default.
• W1946636618 title "Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity." @default.
• W1946636618 cites W1876135160 @default.
• W1946636618 cites W1892579032 @default.
• W1946636618 cites W1911517772 @default.
• W1946636618 cites W201280849 @default.
• W1946636618 cites W2013313438 @default.
• W1946636618 cites W2022059126 @default.
• W1946636618 cites W2079088649 @default.
• W1946636618 cites W2153365867 @default.
• W1946636618 cites W2266212450 @default.
• W1946636618 cites W2298544927 @default.
• W1946636618 cites W2313477330 @default.
• W1946636618 cites W2338649218 @default.
• W1946636618 cites W2341557816 @default.
• W1946636618 cites W262087462 @default.
• W1946636618 doi "https://doi.org/10.1200/jco.1995.13.10.2629" @default.
• W1946636618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7595717" @default.
• W1946636618 hasPublicationYear "1995" @default.
• W1946636618 type Work @default.
• W1946636618 sameAs 1946636618 @default.
• W1946636618 citedByCount "67" @default.
• W1946636618 countsByYear W19466366182012 @default.
• W1946636618 countsByYear W19466366182013 @default.
• W1946636618 countsByYear W19466366182014 @default.
• W1946636618 countsByYear W19466366182015 @default.
• W1946636618 countsByYear W19466366182016 @default.
• W1946636618 countsByYear W19466366182018 @default.
• W1946636618 countsByYear W19466366182019 @default.
• W1946636618 countsByYear W19466366182020 @default.
• W1946636618 countsByYear W19466366182021 @default.
• W1946636618 countsByYear W19466366182023 @default.
• W1946636618 crossrefType "journal-article" @default.
• W1946636618 hasAuthorship W1946636618A5005804337 @default.
• W1946636618 hasAuthorship W1946636618A5015619414 @default.
• W1946636618 hasAuthorship W1946636618A5038734791 @default.
• W1946636618 hasAuthorship W1946636618A5040497223 @default.
• W1946636618 hasAuthorship W1946636618A5049406196 @default.
• W1946636618 hasAuthorship W1946636618A5056213861 @default.
• W1946636618 hasAuthorship W1946636618A5068977568 @default.
• W1946636618 hasAuthorship W1946636618A5076354847 @default.
• W1946636618 hasAuthorship W1946636618A5085647218 @default.
• W1946636618 hasAuthorship W1946636618A5085936617 @default.
• W1946636618 hasConcept C126322002 @default.
• W1946636618 hasConcept C126894567 @default.
• W1946636618 hasConcept C136948725 @default.
• W1946636618 hasConcept C141071460 @default.
• W1946636618 hasConcept C142724271 @default.
• W1946636618 hasConcept C204787440 @default.
• W1946636618 hasConcept C27081682 @default.
• W1946636618 hasConcept C2776694085 @default.
• W1946636618 hasConcept C2776755627 @default.
• W1946636618 hasConcept C2777063308 @default.
• W1946636618 hasConcept C2777506904 @default.
• W1946636618 hasConcept C2777767877 @default.
• W1946636618 hasConcept C2778119113 @default.
• W1946636618 hasConcept C2778256501 @default.
• W1946636618 hasConcept C2778629024 @default.
• W1946636618 hasConcept C2778850193 @default.
• W1946636618 hasConcept C2780376820 @default.
• W1946636618 hasConcept C2780964509 @default.
• W1946636618 hasConcept C2781303535 @default.
• W1946636618 hasConcept C71924100 @default.
• W1946636618 hasConcept C74133956 @default.
• W1946636618 hasConcept C90924648 @default.
• W1946636618 hasConceptScore W1946636618C126322002 @default.
• W1946636618 hasConceptScore W1946636618C126894567 @default.
• W1946636618 hasConceptScore W1946636618C136948725 @default.
• W1946636618 hasConceptScore W1946636618C141071460 @default.
• W1946636618 hasConceptScore W1946636618C142724271 @default.
• W1946636618 hasConceptScore W1946636618C204787440 @default.
• W1946636618 hasConceptScore W1946636618C27081682 @default.
• W1946636618 hasConceptScore W1946636618C2776694085 @default.
• W1946636618 hasConceptScore W1946636618C2776755627 @default.
• W1946636618 hasConceptScore W1946636618C2777063308 @default.
• W1946636618 hasConceptScore W1946636618C2777506904 @default.
• W1946636618 hasConceptScore W1946636618C2777767877 @default.
• W1946636618 hasConceptScore W1946636618C2778119113 @default.
• W1946636618 hasConceptScore W1946636618C2778256501 @default.
• W1946636618 hasConceptScore W1946636618C2778629024 @default.
• W1946636618 hasConceptScore W1946636618C2778850193 @default.
• W1946636618 hasConceptScore W1946636618C2780376820 @default.
• W1946636618 hasConceptScore W1946636618C2780964509 @default.
• W1946636618 hasConceptScore W1946636618C2781303535 @default.
• W1946636618 hasConceptScore W1946636618C71924100 @default.

• next